✦ LIBER ✦

AS-066 Japanese Patient Outcomes in the PLATINUM Randomized Trial Comparing the Platinum Chromium PROMUS Element Everolimus-Eluting Stent to the Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stent in De Novo Coronary Artery Lesions

✍ Scribed by Shigeru Saito; Nobuhisa Hagiwara; Ryuta Asano; Keiichi Igarashi; Toshiya Muramatsu; Junji Yajima; Hiroyoshi Yokoi; Masato Nakamura; Kenshi Fujii; Takaaki Isshiki; Gregg Stone; Paul Teirstein; Ian Meredith; Dominic Allocco; Keith Dawkins

Book ID: 113448950
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 243 KB
Volume: 109
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2012.01.239

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TWO-YEAR RESULTS OF THE PLATINUM RANDOMI

TWO-YEAR RESULTS OF THE PLATINUM RANDOMIZED TRIAL COMPARING PLATINUM CHROMIUM PROMUS ELEMENT AND COBALT CHROMIUM PROMUS/XIENCE V EVEROLIMUS-ELUTING STENTS IN DE NOVO CORONARY ARTERY LESIONS

✍ Gregg W. Stone; Paul Teirstein; Ian Meredith; Alain Bouchard; Didier Carrié; Hel 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 106 KB

A Prospective, Randomized Evaluation of

A Prospective, Randomized Evaluation of a Novel Everolimus-Eluting Coronary Stent: The PLATINUM (A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of up to Two De Novo Coronary Artery Lesions) Trial

✍ Gregg W. Stone; Paul S. Teirstein; Ian T. Meredith; Bruno Farah; Christophe L. D 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 825 KB

TCT-240: PLATINUM QCA: A Prospective, Mu

TCT-240: PLATINUM QCA: A Prospective, Multicenter Trial Assessing Clinical, Angiographic, and Intravascular Ultrasound Outcomes (9 Months) with the Novel Platinum-Chromium Thin-Strut PROMUS Element Everolimus-Eluting Stent in De Novo Coronary Stenoses

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 115 KB

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

ABSORB II randomized controlled trial: A

ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

✍ Roberto Diletti; Patrick W. Serruys; Vasim Farooq; Krishnankutty Sudhir; Cecile 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB